Single-Dose PK Study of GBT440 in Subjects With Renal Impairment

Completed · Phase 1

Conditions studied: Renal Impairment

In brief

A Phase 1, multiple center, nonrandomized, open-label, parallel group study of a single oral dose of GBT440 administered in subjects with mild, moderate, or severe renal impairment disease and healthy subjects with normal renal function.

Key facts

Study ID
NCT03161015
Run by
Global Blood Therapeutics
People needed
16
Starts
2016-11-01
Expected to finish
2017-07-06
Last updated by the study team
2018-02-22

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.